Literature DB >> 25839061

Impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer.

Mark P Pfeifer1, Cynthia Keeney2, Jeffrey Bumpous3, Tara J Schapmire1, Jamie L Studts4, John Myers5, Barbara Head6.   

Abstract

BACKGROUND: Patients undergoing treatment for head and neck cancer commonly experience signi•cant changes in quality of life (QoL) and levels of symptom distress. It is not known if a telehealth intervention would mitigate these changes.
OBJECTIVE: To evaluate the impact of a telehealth intervention on QoL and symptom burden in patients undergoing initial treatment for head and neck cancers.
METHODS: A randomized clinical trial comparing the impact on QoL and symptom distress of telehealth intervention and standard care was conducted with 80 patients (45 treatment, 35 control) who had been diagnosed with head or neck cancer and were receiving 1 or more treatment modalities. Treatment group participants responded daily to symptom management algorithms using a simple telehealth messaging device. QoL was evaluated by the Functional Assessment of Cancer Therapy-Head and Neck Scale (FACTHN) and symptom burden by the Memorial Symptom Assessment Scale (MSAS). Control group participants completed assessments while they received routine care.
RESULTS: In the posttreatment phase, the telehealth participants had signi•cantly better scores than the controls for physical well-being (20.6 vs 17.0, P = .02) and trial outcome index (59.9 vs. 50.2, P = .04) on the FACT-HN, and total scores on the MSAS (0.9 vs. 1.2, P = .04). LIMITATIONS: The moderate sample size of 80 patients limits the power to measure more subtle impacts of the intervention.
CONCLUSIONS: Using telehealth to provide support to patients with head and neck cancer during the acute phase of treatment improved some aspects of posttreatment QoL and symptom burden. ©2015 Frontline Medical Communications.

Entities:  

Keywords:  head and neck cancer; quality of life; supportive oncology; telehealth

Year:  2015        PMID: 25839061      PMCID: PMC6935317          DOI: 10.12788/jcso.0101

Source DB:  PubMed          Journal:  J Community Support Oncol        ISSN: 2330-7749


  34 in total

1.  The memorial symptom assessment scale short form (MSAS-SF).

Authors:  V T Chang; S S Hwang; M Feuerman; B S Kasimis; H T Thaler
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

2.  Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck.

Authors:  Nadine P Connor; Stacy B Cohen; Rachael E Kammer; Paula A Sullivan; Kathryn A Brewer; Theodore S Hong; Richard J Chappell; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

3.  Effect of telecare management on pain and depression in patients with cancer: a randomized trial.

Authors:  Kurt Kroenke; Dale Theobald; Jingwei Wu; Kelli Norton; Gwendolyn Morrison; Janet Carpenter; Wanzhu Tu
Journal:  JAMA       Date:  2010-07-14       Impact factor: 56.272

4.  Impact on quality of life of a telemedicine system supporting head and neck cancer patients: a controlled trial during the postoperative period at home.

Authors:  Jaap L van den Brink; Peter W Moorman; Maarten F de Boer; Wim C J Hop; Jean F A Pruyn; Carel D A Verwoerd; Jan H van Bemmel
Journal:  J Am Med Inform Assoc       Date:  2007-01-09       Impact factor: 4.497

Review 5.  Psychosocial interventions for patients with head and neck cancer: past, present, and future.

Authors:  Cherith J Semple; Kate Sullivan; Lynn Dunwoody; W George Kernohan
Journal:  Cancer Nurs       Date:  2004 Nov-Dec       Impact factor: 2.592

6.  Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment.

Authors:  V T Chang; S S Hwang; M Feuerman; B S Kasimis
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

7.  The symptom burden of chronic critical illness.

Authors:  Judith E Nelson; Diane E Meier; Ann Litke; Dana A Natale; Robert E Siegel; R Sean Morrison
Journal:  Crit Care Med       Date:  2004-07       Impact factor: 7.598

8.  Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale.

Authors:  Joan E Tranmer; Daren Heyland; Debra Dudgeon; Dianne Groll; Mae Squires-Graham; Kathy Coulson
Journal:  J Pain Symptom Manage       Date:  2003-05       Impact factor: 3.612

9.  The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

Authors:  R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  Clinical predictors of quality of life in patients with head and neck cancer.

Authors:  Jeffrey E Terrell; David L Ronis; Karen E Fowler; Carol R Bradford; Douglas B Chepeha; Mark E Prince; Theodoros N Teknos; Gregory T Wolf; Sonia A Duffy
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-04
View more
  2 in total

1.  The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.

Authors:  Jung Julie Kang; Richard J Wong; Eric J Sherman; Alisa Rybkin; Sean M McBride; Nadeem Riaz; C Jillian Tsai; Yao Yu; Linda Chen; Kaveh Zakeri; Daphna Y Gelblum; Erin F Gillespie; Marc A Cohen; Jennifer R Cracchiolo; Ian Ganly; Snehal Patel; Bhuvanesh Singh; Jay O Boyle; Benjamin R Roman; Luc G Morris; Ashok R Shaha; Lara A Dunn; Alan L Ho; James V Fetten; Jatin P Shah; David G Pfister; Nancy Y Lee
Journal:  Cancer       Date:  2020-07-08       Impact factor: 6.921

Review 2.  Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives.

Authors:  M Aapro; P Bossi; A Dasari; L Fallowfield; P Gascón; M Geller; K Jordan; J Kim; K Martin; S Porzig
Journal:  Support Care Cancer       Date:  2020-06-12       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.